Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657797 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 656
- Enrollment target
NCT03657797 is a Phase 2 study that has completed, run by Nicox Ophthalmics. The registered enrollment target is 656 participants.
The verdict
NCT03657797, a Phase 2 study, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 656 participants
- Enrollment target
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.
Interventions
- DRUG Latanoprost 0.005%
- DRUG NCX 470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 656 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03657797
The ClinicalTrials.gov registry entry for NCT03657797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 656 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicox Ophthalmics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Latanoprost 0.005% is the first listed.
NCT03657797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03657797 about?
NCT03657797 is a clinical study titled "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) wi...
What is the current status of trial NCT03657797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 656 participants. The study started on 2018-08-01. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT03657797?
The interventions under investigation include: Latanoprost 0.005% (DRUG), NCX 470 (DRUG).
Who is sponsoring clinical trial NCT03657797?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.